Literature DB >> 3280279

Pentamidine therapy in renal failure: case report and literature review.

W E Fitzsimmons1, S S Luskin.   

Abstract

The literature lacks adequate dosing guidelines for modifying pentamidine therapy in renal failure. This report describes a patient in renal failure undergoing intermittent peritoneal dialysis who is treated with pentamidine for Pneumocystis carinii pneumonia. Data on pentamidine's disposition are reviewed.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3280279     DOI： 10.1177/106002808802200104

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN： 0012-6578


  6 in total

Review 1.  Pentamidine. A risk-benefit analysis.

Authors:  B Wispelwey; R Pearson
Journal:  Drug Saf       Date:  1990 May-Jun       Impact factor: 5.606

Review 2.  Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia.

Authors:  H F Vöhringer; K Arastéh
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

4.  Stout camphor tree genome fills gaps in understanding of flowering plant genome evolution.

Authors:  Shu-Miaw Chaw; Isheng J Tsai; Yu-Ching Liu; Yu-Wei Wu; Han-Yu Wang; Chan-Yi Ivy Lin; Chung-Shien Wu; Huei-Mien Ke; Lo-Yu Chang; Chih-Yao Hsu; Hui-Ting Yang; Edi Sudianto; Min-Hung Hsu; Kun-Pin Wu; Ling-Ni Wang; James H Leebens-Mack
Journal:  Nat Plants       Date:  2019-01-09       Impact factor: 15.793

5.  Comparative genomics of the major parasitic worms.

Authors: 
Journal:  Nat Genet       Date:  2018-11-05       Impact factor: 38.330

6.  The conifer root rot pathogens Heterobasidion irregulare and Heterobasidion occidentale employ different strategies to infect Norway spruce.

Authors:  Yang Hu; Malin Elfstrand; Jan Stenlid; Mikael Brandström Durling; Åke Olson
Journal:  Sci Rep       Date:  2020-04-03       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.